An assessment of breast cancer HER2, ER, and PR expressions based on mammography using deep learning with convolutional neural networks.
Journal:
Scientific reports
PMID:
39924532
Abstract
Mammography is the recommended imaging modality for breast cancer screening. Expressions of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) are critical to the development of therapeutic strategies for breast cancer. In this study, a deep learning model (CBAM ResNet-18) was developed to predict the expression of these three receptors on mammography without manual segmentation of masses. Mammography of patients with pathologically proven breast cancer was obtained from two centers. A deep learning-based model (CBAM ResNet-18) for predicting HER2, ER, and PR expressions was trained and validated using five-fold cross-validation on a training dataset. The performance of the model was further tested using an external test dataset. Area under receiver operating characteristic curve (AUC), accuracy (ACC), and F1-score were calculated to assess the ability of the model to predict each receptor. For comparison we also developed original ResNet-18 without attention module and VGG-19 with and without attention module. The AUC (95% CI), ACC, and F1-score were 0.708 (0.609, 0.808), 0.651, 0.528, respectively, in the HER2 test dataset; 0.785 (0.673, 0.897), 0.845, 0.905, respectively, in the ER test dataset; and 0.706 (0.603, 0.809), 0.678, 0.773, respectively, in the PR test dataset. The proposed model demonstrates superior performance compared to the original ResNet-18 without attention module and VGG-19 with and without attention module. The model has the potential to predict HER2, PR, and especially ER expressions, and thus serve as an adjunctive diagnostic tool for breast cancer.